Email updates

Keep up to date with the latest news and content from ISSO and BioMed Central.

Open Access Commentary

Epithelial-myoepithelial carcinoma of the parotid gland, unusual malignancy radiologically simulating a benign lesion: case report

Irene Piscioli, Luca Morelli, Andrea Falzone, Franca Del Nonno, Marinella Neri, Zorika Christiana Di Rocco, Alessia Catalucci, Salvatore Donato and Stefano Licci*

International Seminars in Surgical Oncology 2007, 4:25  doi:10.1186/1477-7800-4-25

PubMed Commons is an experimental system of commenting on PubMed abstracts, introduced in October 2013. Comments are displayed on the abstract page, but during the initial closed pilot, only registered users can read or post comments. Any researcher who is listed as an author of an article indexed by PubMed is entitled to participate in the pilot. If you would like to participate and need an invitation, please email info@biomedcentral.com, giving the PubMed ID of an article on which you are an author. For more information, see the PubMed Commons FAQ.

Oncological Terrain and Inherited Oncological Real Risk: New Way in Malignancy Primary Prevention and early Diagnosis.

Sergio Stagnaro   (2007-12-06 09:04)  Biophysical Semeiotics Reserach Laboratory email

Editors,

the paper's authors write "Ultrasound (US), Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) are widely used in the clinical diagnosis of parotid gland tumors and their efficacy in identifying benign lesions is well documented" (1). And then? Unfortunately, these italian Colleagues ignore Biophysical Semeiotics (www.semeioticabiofisica.it), that allows doctors to recognize at the bedside - since birth - Oncological Terrain "and" Inherited oncological Real Risk in every biological systems (2-8). In fact, all around the world authors ignore or overlook the existence of Oncological Terrain (http://www.semeioticabiofisica.it) as well as bed-side recognizing cancer inherited “real” risk, in a quantitative way (2-8).

Consequently, all authors think "wrongly" that “all” individuals must urdergo to cancer markers and other screening measures, as those cited in the article, therefore spending uselessly NHS money, and physician’s energy and time, because physicians think ERRONEOUSLY that everybody can be involved by malignacy. As a matter of fact, a subject can be involved by Oncological Terrain, even with or without precise location of “congenital cancer real risk” in a well defined tissue (“ab posse ad esse non licet illatio”, Kant, Kritik der reinigen Vernunft) (5). I think that because congenital functional mitochondrial cytopathology is overlooked, "conditio sine qua non" of the most frequent and dangerous human disorders, including malignancies, current clinical researches are fundamentally biased. In other words, one does not consider the existence or assess the seriousness as well as the location of Congenital Acidosic Enzyme-Metabolic Histangiopathy (in above-cited web-site), conditio sine qua non of both Oncological Terrain and, consequently cancer “real risk” (2-8). In fact, both environmental risk factors and every drug, including, e.g., oestrogens, suggested as a risk factor for breast cancer, "could" influence some human biological functions and/or bring about different disorders, such as cancers, exclusively in relation to both the presence and intensity of CAEMH in a well-defined biological system. Before all sophysticated semeiotics, as indicated by the authors, physicians have to performe an accurate, up-dated, physical examination, reliable to recognize Oncological Terrain “and” Inherited (sic!) Oncological Real Risk, in our case obviously in the parotid gland! Under such as condition I utilize Coniugated Melatonin, according to Di Bella-Ferrari, associated with NIR-LED local applications (2, 3,5).

In conclusion, we need at first (i.e., starting whatever screening or research) to investigate the presence and intensity of CAEMH in the "tested" population, i.e. in "every", "single" patient, and soon thereafter assessing presence, intensity of the "Oncological Terrain", and the precise location of Congenital cancer “real risk”, both always develop on the basis of the above -mentioned congenital mitochondrial cytopathology. In fact, without this alteration of psycho-neuro-endocrine-immunological system, oncogenesis is not possible, as allows me to state a 46-year-long clinical experience with Biophysical Semeiotics, Single Patient Based Medicine theory is based on (7). The importance of the above-mentioned congenital constitution should not be overlooked, particularly when we assess a "possible" risk factor for cancer and then for cancer screening.

1) Piscioli Irene, et al. Epithelial-myoepithelial carcinoma of the parotid gland, unusual malignancy radiologically simulating a benign lesion: case report. International Seminars in Surgical Oncology 2007, 4:25doi:10.1186/1477-7800-4-2

2) Stagnaro-Neri M., Stagnaro S. Introduzione alla Semeiotica Biofisica. Il Terreno Oncologico. Travel Factory, Roma, 2004. http://www.travelfactory.it/semeiotica_biofisica.htm

3) Stagnaro-Neri M., Stagnaro S. Cancro della mammella: prevenzione primaria e diagnosi precoce con la percussione ascoltata. Gazz. Med. It. – Arch. Sc. Med. 152, 447, 1993

4) Stagnaro Sergio. GPs , Biophysical Semeiotics, and bedside cancer diagnosis. 08 July 2007, International Seminar of Surgical Oncology, http://www.issoonline.com/content/4/1/11/comments#281539 . 2007

5) Stagnaro S. Stagnaro S., Stagnaro-Neri M., La Melatonina nella Terapia del Terreno Oncologico e del “Reale Rischio” Oncologico. Travel Factory, Roma, 2004. http://www.travelfactory.it/semeiotica_biofisica_2.htm

6) Sergio Stagnaro. Mitochondrial Bed-Side Evaluation: a new Way in the War against Cancer (21 December 2005). Cancer Cell International http://www.cancerci.com/content/5/1/34/comments#218502

7) Stagnaro S., Stagnaro-Neri M., Single Patient Based Medicine.La Medicina Basata sul Singolo Paziente: Nuove Indicazioni della Melatonina. Travel Factory, Roma, 2005. http://www.travelfactory.it/libro_singlepatientbased.htm

8) Stagnaro Sergio. Reale Rischio Semeiotico-Biofisico. I dispositivi Endoarteriolari di Blocco neoformati-patologici, tipo I, sottotipo a) oncologici e b) aspecifici. Ed Travel Factory, Roma www.travelfactory.it, in press.

Competing interests

None declared

top

Post a comment